Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Gemcitabine 8durvalumab 7Cisplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Specimen Handling 5Fluorouracil 5Biopsy 5Paclitaxel 4Folfox protocol 4Taxes 3Irinotecan 3pemigatinib 2pembrolizumab 2olaparib 2futibatinib 2fludarabine 2dehydroftorafur 2Platinum 2Nivolumab 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Carboplatin 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1zanidatamab 1ulixertinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Cytochrome P-450 CYP2B6 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡